Indalo’s strategy to address the unmet medical needs in fibrosis is to disrupt integrin-mediated activation of TGF-β. Using a rational drug-design approach, we have developed a robust portfolio of novel small molecules that bind to targeted integrins with high potency and selectivity. Our portfolio comprises multiple estates of integrin-binding small molecules featuring diverse properties and target specificities. These include orally bioavailable compounds that broadly target RGD-binding integrins central to fibrotic responses, as well as compounds that target more restricted subsets of RGD-binding integrins.
Compounds in our portfolio have demonstrated strong activity in preclinical models of renal, hepatic, pulmonary, pancreatic, cardiac, muscular, and surgical implant fibrosis. We intend to exploit our broad pallet of chemical matter to address unmet needs in multiple therapeutic areas.